Published in Antimicrob Agents Chemother on March 01, 2001
Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev (2008) 17.77
Metallo-beta-lactamases: the quiet before the storm? Clin Microbiol Rev (2005) 12.07
Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A beta-lactamase, KPC-3, in a New York Medical Center. Antimicrob Agents Chemother (2004) 7.99
Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother (2007) 7.84
Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev (2012) 5.65
Evaluation of the Hodge test and the imipenem-EDTA double-disk synergy test for differentiating metallo-beta-lactamase-producing isolates of Pseudomonas spp. and Acinetobacter spp. J Clin Microbiol (2003) 4.79
Characterization of OXA-25, OXA-26, and OXA-27, molecular class D beta-lactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother (2001) 4.15
bla(VIM-2) cassette-containing novel integrons in metallo-beta-lactamase-producing Pseudomonas aeruginosa and Pseudomonas putida isolates disseminated in a Korean hospital. Antimicrob Agents Chemother (2002) 4.01
OXA-58, a novel class D {beta}-lactamase involved in resistance to carbapenems in Acinetobacter baumannii. Antimicrob Agents Chemother (2005) 3.63
Evaluation of a new Etest for detecting metallo-beta-lactamases in routine clinical testing. J Clin Microbiol (2002) 3.38
Rapid detection and identification of metallo-beta-lactamase-encoding genes by multiplex real-time PCR assay and melt curve analysis. J Clin Microbiol (2006) 3.30
Genetic and functional analysis of the chromosome-encoded carbapenem-hydrolyzing oxacillinase OXA-40 of Acinetobacter baumannii. Antimicrob Agents Chemother (2003) 3.19
Nosocomial outbreak of carbapenem-resistant Pseudomonas aeruginosa with a new bla(IMP) allele, bla(IMP-7). Antimicrob Agents Chemother (2002) 2.97
Detection of Pseudomonas aeruginosa producing metallo-beta-lactamases in a large centralized laboratory. J Clin Microbiol (2005) 2.89
The Acinetobacter baumannii Oxymoron: Commensal Hospital Dweller Turned Pan-Drug-Resistant Menace. Front Microbiol (2012) 2.45
IMP-12, a new plasmid-encoded metallo-beta-lactamase from a Pseudomonas putida clinical isolate. Antimicrob Agents Chemother (2003) 1.77
Biochemical characterization of the acquired metallo-beta-lactamase SPM-1 from Pseudomonas aeruginosa. Antimicrob Agents Chemother (2003) 1.75
Endemic carbapenem resistance associated with OXA-40 carbapenemase among Acinetobacter baumannii isolates from a hospital in northern Spain. J Clin Microbiol (2002) 1.67
Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized beta-lactamases. Antimicrob Agents Chemother (2004) 1.65
Molecular analysis of metallo-beta-lactamase gene bla(SPM-1)-surrounding sequences from disseminated Pseudomonas aeruginosa isolates in Recife, Brazil. Antimicrob Agents Chemother (2004) 1.60
Molecular epidemiology of sequential outbreaks of Acinetobacter baumannii in an intensive care unit shows the emergence of carbapenem resistance. J Clin Microbiol (2004) 1.56
Class 1 integron containing metallo-beta-lactamase gene blaVIM-2 in Pseudomonas aeruginosa clinical strains isolated in Japan. Antimicrob Agents Chemother (2004) 1.52
Integron carrying a novel metallo-beta-lactamase gene, blaIMP-16, and a fused form of aminoglycoside-resistant gene aac(6')-30/aac(6')-Ib': report from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother (2004) 1.51
bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. Antimicrob Agents Chemother (2008) 1.46
Epidemiology of rifampin ADP-ribosyltransferase (arr-2) and metallo-beta-lactamase (blaIMP-4) gene cassettes in class 1 integrons in Acinetobacter strains isolated from blood cultures in 1997 to 2000. Antimicrob Agents Chemother (2003) 1.44
Molecular characterization of integrons in epidemiologically unrelated clinical isolates of Acinetobacter baumannii from Italian hospitals reveals a limited diversity of gene cassette arrays. Antimicrob Agents Chemother (2002) 1.36
Phenotypic, biochemical, and molecular techniques for detection of metallo-β-lactamase NDM in Acinetobacter baumannii. J Clin Microbiol (2012) 1.32
Incidence of class 1 integrons in a quaternary ammonium compound-polluted environment. Antimicrob Agents Chemother (2005) 1.28
Identification of residues critical for metallo-beta-lactamase function by codon randomization and selection. Protein Sci (2001) 1.23
Carbapenem-resistant Klebsiella pnuemoniae in Singapore producing IMP-1 beta-lactamase and lacking an outer membrane protein. Antimicrob Agents Chemother (2001) 1.22
Detection of a variant metallo-beta-lactamase, IMP-10, from two unrelated strains of Pseudomonas aeruginosa and an alcaligenes xylosoxidans strain. Antimicrob Agents Chemother (2002) 1.22
Genomic comparison of multi-drug resistant invasive and colonizing Acinetobacter baumannii isolated from diverse human body sites reveals genomic plasticity. BMC Genomics (2011) 1.18
Efficacy of beta-lactams for treating experimentally induced pneumonia due to a carbapenem-hydrolyzing metallo-beta-lactamase-producing strain of Pseudomonas aeruginosa. Antimicrob Agents Chemother (2002) 1.11
Characterization of the carbapenem-hydrolyzing oxacillinase oxa-58 in an Acinetobacter genospecies 3 clinical isolate. Antimicrob Agents Chemother (2008) 1.10
Carbapenem-resistant Pseudomonas aeruginosa in malaysia producing IMP-7 beta-lactamase. Antimicrob Agents Chemother (2002) 1.06
Presence of Pseudomonas putida strains harboring plasmids bearing the metallo-beta-lactamase gene bla(IMP) in a hospital in Japan. J Clin Microbiol (2003) 1.05
pEl1573 Carrying blaIMP-4, from Sydney, Australia, is closely related to other IncL/M plasmids. Antimicrob Agents Chemother (2012) 1.01
In vitro activity of tigecycline and comparators against carbapenem-susceptible and resistant Acinetobacter baumannii clinical isolates in Italy. Ann Clin Microbiol Antimicrob (2008) 0.99
Carbapenemases in enterobacteria, Hong Kong, China, 2009. Emerg Infect Dis (2011) 0.98
Dominance of IMP-4-producing enterobacter cloacae among carbapenemase-producing Enterobacteriaceae in Australia. Antimicrob Agents Chemother (2015) 0.98
Genetic variability among ampC genes from acinetobacter genomic species 3. Antimicrob Agents Chemother (2008) 0.97
Type 1 integrons in epidemiologically unrelated Acinetobacter baumannii isolates collected at Spanish hospitals. Antimicrob Agents Chemother (2004) 0.97
Molecular characterization of the gene encoding a new AmpC beta-lactamase in a clinical strain of acinetobacter genomic species 3. Antimicrob Agents Chemother (2004) 0.96
bla(IMP-9) and its association with large plasmids carried by Pseudomonas aeruginosa isolates from the People's Republic of China. Antimicrob Agents Chemother (2006) 0.95
Antimicrobial resistance in Acinetobacter baumannii: From bench to bedside. World J Clin Cases (2014) 0.88
Modified Hodge test: A simple and effective test for detection of carbapenemase production. Iran J Microbiol (2011) 0.87
A case of IMP-4-, OXA-421-, OXA-96-, and CARB-2-producing Acinetobacter pittii sequence type 119 in Australia. J Clin Microbiol (2014) 0.81
Spread of carbapenemase-producing enterobacteria in a southwest hospital in China. Ann Clin Microbiol Antimicrob (2014) 0.80
Assessment of Biofilm Formation and Resistance to Imipenem and Ciprofloxacin among Clinical Isolates of Acinetobacter baumannii in Tehran. Jundishapur J Microbiol (2014) 0.80
Multidrug-resistant ST235 Pseudomonas aeruginosa clinical isolates producing IMP-26 with increased carbapenem hydrolyzing activities in Vietnam. Antimicrob Agents Chemother (2016) 0.78
Identification of Acinetobacter genomic species 13TU by sequence analysis of the 16S-23S rRNA gene spacer region. J Clin Microbiol (2009) 0.77
Isolation of the first IMP-4 metallo-β-lactamase producing Klebsiella pneumoniae in Tianjin, China. Braz J Microbiol (2012) 0.76
Insights on the Horizontal Gene Transfer of Carbapenemase Determinants in the Opportunistic Pathogen Acinetobacter baumannii. Microorganisms (2016) 0.75
Biology of Acinetobacter baumannii: Pathogenesis, Antibiotic Resistance Mechanisms, and Prospective Treatment Options. Front Cell Infect Microbiol (2017) 0.75
Genome and Plasmid Analysis of blaIMP-4 -Carrying Citrobacter freundii B38. Antimicrob Agents Chemother (2016) 0.75
Plasmid interference for curing antibiotic resistance plasmids in vivo. PLoS One (2017) 0.75
Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev (1996) 13.25
Molecular characterization of an enterobacterial metallo beta-lactamase found in a clinical isolate of Serratia marcescens that shows imipenem resistance. Antimicrob Agents Chemother (1994) 8.64
Interspecies transformation of Acinetobacter: genetic evidence for a ubiquitous genus. J Bacteriol (1972) 7.49
Carbapenem-hydrolyzing beta-lactamases. Antimicrob Agents Chemother (1997) 7.17
Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother (1991) 7.10
PCR detection of metallo-beta-lactamase gene (blaIMP) in gram-negative rods resistant to broad-spectrum beta-lactams. J Clin Microbiol (1996) 6.68
A novel integron-like element carrying the metallo-beta-lactamase gene blaIMP. Antimicrob Agents Chemother (1995) 6.00
Appearance of IMP-1 metallo-beta-lactamase in Europe. Lancet (1999) 5.41
Multifocal outbreaks of metallo-beta-lactamase-producing Pseudomonas aeruginosa resistant to broad-spectrum beta-lactams, including carbapenems. Antimicrob Agents Chemother (1996) 5.36
A guide to sensitivity testing. Report of the Working Party on Antibiotic Sensitivity Testing of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother (1991) 5.31
Characterization of the metallo-beta-lactamase determinant of Acinetobacter baumannii AC-54/97 reveals the existence of bla(IMP) allelic variants carried by gene cassettes of different phylogeny. Antimicrob Agents Chemother (2000) 5.26
Structure of In31, a blaIMP-containing Pseudomonas aeruginosa integron phyletically related to In5, which carries an unusual array of gene cassettes. Antimicrob Agents Chemother (1999) 4.24
Characterization of OXA-25, OXA-26, and OXA-27, molecular class D beta-lactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother (2001) 4.15
OXA-24, a novel class D beta-lactamase with carbapenemase activity in an Acinetobacter baumannii clinical strain. Antimicrob Agents Chemother (2000) 4.08
Sequence analysis of ARI-1, a novel OXA beta-lactamase, responsible for imipenem resistance in Acinetobacter baumannii 6B92. Antimicrob Agents Chemother (2000) 3.85
Amino acid substitutions in a variant of IMP-1 metallo-beta-lactamase. Antimicrob Agents Chemother (2000) 3.03
Worldwide emergence of carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother (1998) 2.94
Carbapenem-hydrolysing IMP-1 beta-lactamase in Klebsiella pneumoniae from Singapore. Lancet (1999) 2.68
Imipenem resistance in Acinetobacter baumanii is due to altered penicillin-binding proteins. Chemotherapy (1991) 2.60
Imipenem resistance among Acinetobacter baumannii: association with reduced expression of a 33-36 kDa outer membrane protein. J Antimicrob Chemother (1996) 2.60
Detection of carbapenemase-producing Acinetobacter baumannii in a hospital. J Clin Microbiol (2000) 2.29
Evaluation of amplified ribosomal DNA restriction analysis for identification of Acinetobacter genomic species. Syst Appl Microbiol (1998) 2.20
Oxacillin-hydrolyzing beta-lactamase involved in resistance to imipenem in Acinetobacter baumannii. FEMS Microbiol Lett (1997) 1.76
Limitation of Acinetobacter baumannii treatment by plasmid-mediated carbapenemase ARI-2. Lancet (1998) 1.75
Extended-spectrum beta-lactamase-producing strain of Acinetobacter baumannii isolated from a patient in France. J Antimicrob Chemother (1999) 1.71
Biochemical characteristics of a carbapenemase from an Acinetobacter baumannii isolate collected in Buenos Aires, Argentina. J Antimicrob Chemother (1999) 1.70
Mono- and binuclear Zn2+-beta-lactamase. Role of the conserved cysteine in the catalytic mechanism. J Biol Chem (1999) 1.41
Prevalence of Acinetobacter spp. isolates with reduced susceptibility to imipenem, as determined by a USA-wide electronic surveillance network. J Antimicrob Chemother (1999) 1.01
Persistence of sulphonamide resistance in Escherichia coli in the UK despite national prescribing restriction. Lancet (2001) 6.37
Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: resistance to tetracycline, chloramphenicol, and norfloxacin. Antimicrob Agents Chemother (1994) 4.87
Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect (2012) 4.68
Outbreak of infections caused by Pseudomonas aeruginosa producing VIM-1 carbapenemase in Greece. J Clin Microbiol (2000) 4.67
Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: active efflux as a contributing factor to beta-lactam resistance. Antimicrob Agents Chemother (1994) 4.43
Characterization of OXA-25, OXA-26, and OXA-27, molecular class D beta-lactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother (2001) 4.15
Carbapenemases: a problem in waiting? Curr Opin Microbiol (2000) 3.98
High-level vancomycin-resistant enterococci causing hospital infections. Epidemiol Infect (1989) 3.95
Resistance to vancomycin and teicoplanin: an emerging clinical problem. Clin Microbiol Rev (1990) 3.82
Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum beta-lactamases in the UK. J Antimicrob Chemother (2004) 3.69
Identification and screening of carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect (2012) 3.58
Dominance of EMRSA-15 and -16 among MRSA causing nosocomial bacteraemia in the UK: analysis of isolates from the European Antimicrobial Resistance Surveillance System (EARSS). J Antimicrob Chemother (2001) 3.51
Cloning and sequence analysis of the gene for a carbapenem-hydrolyzing class A beta-lactamase, Sme-1, from Serratia marcescens S6. Antimicrob Agents Chemother (1994) 3.34
Biochemical characterization of a beta-lactamase that hydrolyzes penems and carbapenems from two Serratia marcescens isolates. Antimicrob Agents Chemother (1990) 3.32
Carbapenem-non-susceptible Enterobacteriaceae in Europe: conclusions from a meeting of national experts. Euro Surveill (2010) 3.22
Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis. BMJ (2000) 3.10
OXA-11, an extended-spectrum variant of OXA-10 (PSE-2) beta-lactamase from Pseudomonas aeruginosa. Antimicrob Agents Chemother (1993) 3.09
Worldwide emergence of carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother (1998) 2.94
Penicillin-resistant viridans streptococci have obtained altered penicillin-binding protein genes from penicillin-resistant strains of Streptococcus pneumoniae. Proc Natl Acad Sci U S A (1990) 2.82
Emergence and spread of vancomycin resistance among enterococci in Europe. Euro Surveill (2008) 2.78
Detection of the mec-A gene and phenotypic detection of resistance in Staphylococcus aureus isolates with borderline or low-level methicillinresistance. J Antimicrob Chemother (1996) 2.77
OXA-14, another extended-spectrum variant of OXA-10 (PSE-2) beta-lactamase from Pseudomonas aeruginosa. Antimicrob Agents Chemother (1995) 2.77
A sensitive and specific phenotypic assay for detection of metallo-β-lactamases and KPC in Klebsiella pneumoniae with the use of meropenem disks supplemented with aminophenylboronic acid, dipicolinic acid and cloxacillin. Clin Microbiol Infect (2011) 2.74
Carbapenem-hydrolysing IMP-1 beta-lactamase in Klebsiella pneumoniae from Singapore. Lancet (1999) 2.68
Carbapenemase-producing Enterobacteriaceae in Europe: a survey among national experts from 39 countries, February 2013. Euro Surveill (2013) 2.63
Mechanisms of resistance to beta-lactam antibiotics amongst Pseudomonas aeruginosa isolates collected in the UK in 1993. J Med Microbiol (1995) 2.59
Activity of clavulanate combinations against TEM-1 beta-lactamase-producing Escherichia coli isolates obtained in 1982 and 1989. J Antimicrob Chemother (1991) 2.59
Epidemiological typing of klebsiellae with extended-spectrum beta-lactamases from European intensive care units. J Antimicrob Chemother (1998) 2.51
Characterization of the plasmid mediated beta-lactamase BIL-1. J Antimicrob Chemother (1992) 2.48
Complexity and diversity of Klebsiella pneumoniae strains with extended-spectrum beta-lactamases isolated in 1994 and 1996 at a teaching hospital in Durban, South Africa. Antimicrob Agents Chemother (2001) 2.47
Resistance to extended-spectrum cephalosporins, caused by PER-1 beta-lactamase, in Salmonella typhimurium from Istanbul, Turkey. J Med Microbiol (1995) 2.46
Phylogenetic diversity of Escherichia coli strains producing NDM-type carbapenemases. J Antimicrob Chemother (2011) 2.46
Beta-lactamase lability and inducer power of newer beta-lactam antibiotics in relation to their activity against beta-lactamase-inducibility mutants of Pseudomonas aeruginosa. J Infect Dis (1987) 2.37
Enterococcus faecium with high-level resistance to gentamicin. Lancet (1991) 2.28
OXA-15, an extended-spectrum variant of OXA-2 beta-lactamase, isolated from a Pseudomonas aeruginosa strain. Antimicrob Agents Chemother (1997) 2.28
Antimicrobial resistance amongst Klebsiella spp. collected from intensive care units in Southern and Western Europe in 1997-1998. J Antimicrob Chemother (2000) 2.27
Transferable production of PER-1 beta-lactamase in Pseudomonas aeruginosa. J Antimicrob Chemother (1995) 2.26
Penicillin levels in blood and CSF achieved by treatment of syphilis. JAMA (1979) 2.17
Molecular characterization of plasmids encoding CTX-M-15 beta-lactamases from Escherichia coli strains in the United Kingdom. J Antimicrob Chemother (2006) 2.12
Adaptive resistance to aminoglycoside antibiotics from first-exposure down-regulation. J Infect Dis (1990) 2.11
Twenty months of screening for glycopeptide-intermediate Staphylococcus aureus. J Antimicrob Chemother (2000) 2.07
Lack of upward creep of glycopeptide MICs for methicillin-resistant Staphylococcus aureus (MRSA) isolated in the UK and Ireland 2001-07. J Antimicrob Chemother (2012) 2.04
Survey of the prevalence of beta-lactamases amongst 1000 gram-negative bacilli isolated consecutively at the Royal London Hospital. J Antimicrob Chemother (1992) 2.00
Activity of chequerboard combinations of ceftaroline and NXL104 versus beta-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother (2010) 1.83
In-vitro activity of the monobactam, SQ 26,776, against Gram-negative bacteria and its stability to their beta-lactamases. J Antimicrob Chemother (1981) 1.78
Acinetobacter spp. isolates with reduced susceptibilities to carbapenems in a UK burns unit. J Antimicrob Chemother (1998) 1.77
Outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-8, a novel metallo-beta-lactamase, in a tertiary care center in Cali, Colombia. J Clin Microbiol (2004) 1.77
Effect of medium type, age and aeration on the MICs of tigecycline and classical tetracyclines. J Antimicrob Chemother (2005) 1.73
DNA banding pattern polymorphism in vancomycin-resistant Enterococcus faecium and criteria for defining strains. J Clin Microbiol (1999) 1.71
Biochemical characteristics of a carbapenemase from an Acinetobacter baumannii isolate collected in Buenos Aires, Argentina. J Antimicrob Chemother (1999) 1.70
Carbapenemases of Chryseobacterium (Flavobacterium) meningosepticum: distribution of blaB and characterization of a novel metallo-beta-lactamase gene, blaB3, in the type strain, NCTC 10016. Antimicrob Agents Chemother (2000) 1.68
Interactions of tazobactam and clavulanate with inducibly- and constitutively-expressed Class I beta-lactamases. J Antimicrob Chemother (1990) 1.67
Post-mortem radiology--a new sub-speciality? Clin Radiol (2008) 1.67
Characterization of an LysR family protein, SmeR from Serratia marcescens S6, its effect on expression of the carbapenem-hydrolyzing beta-lactamase Sme-1, and comparison of this regulator with other beta-lactamase regulators. Antimicrob Agents Chemother (1995) 1.67
Endemic carbapenem resistance associated with OXA-40 carbapenemase among Acinetobacter baumannii isolates from a hospital in northern Spain. J Clin Microbiol (2002) 1.67
Antimicrobial resistance amongst enterococci isolated in the United Kingdom: a reference laboratory perspective. J Antimicrob Chemother (1993) 1.65
Clinical relevance of laboratory-reported antibiotic resistance in acute uncomplicated urinary tract infection in primary care. J Antimicrob Chemother (2006) 1.64
Colonization of residents and staff of a long-term-care facility and adjacent acute-care hospital geriatric unit by multiresistant bacteria. Clin Microbiol Infect (2009) 1.63
Are SHV beta-lactamases universal in Klebsiella pneumoniae? Antimicrob Agents Chemother (2000) 1.61
Molecular analysis of diverse elements mediating VanA glycopeptide resistance in enterococci. J Antimicrob Chemother (1998) 1.61
Mechanisms of resistance to quinupristin-dalfopristin among isolates of Enterococcus faecium from animals, raw meat, and hospital patients in Western Europe. Antimicrob Agents Chemother (2000) 1.61
Type characterisation and antibiotic susceptibility of Burkholderia (Pseudomonas) cepacia isolates from patients with cystic fibrosis in the United Kingdom and the Republic of Ireland. J Med Microbiol (1996) 1.60
Activity of mecillinam against ESBL producers in vitro. J Antimicrob Chemother (2005) 1.60
Interactions of meropenem with class I chromosomal beta-lactamases. J Antimicrob Chemother (1989) 1.60
Carbapenemase-producing Pseudomonas aeruginosa in UK. Lancet (1998) 1.57
Increasing prevalence of methicillin resistance amongst Staphylococcus aureus blood culture isolates. J Antimicrob Chemother (1999) 1.56
Detection of extended-spectrum beta-lactamases in klebsiellae with the Oxoid combination disk method. J Clin Microbiol (2000) 1.55
Permeability to carbapenems of Proteus mirabilis mutants selected for resistance to imipenem or other beta-lactams. J Antimicrob Chemother (1997) 1.55
In vitro activities of Ro 17-2301 and aztreonam compared with those of other new beta-lactam antibiotics against clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother (1985) 1.54
Skin carriage of acinetobacters in Hong Kong. J Clin Microbiol (1999) 1.53
Multiresistant serotype O 12 Pseudomonas aeruginosa: evidence for a common strain in Europe. Epidemiol Infect (1989) 1.53
OXA-17, a further extended-spectrum variant of OXA-10 beta-lactamase, isolated from Pseudomonas aeruginosa. Antimicrob Agents Chemother (1999) 1.49
OXA-16, a further extended-spectrum variant of OXA-10 beta-lactamase, from two Pseudomonas aeruginosa isolates. Antimicrob Agents Chemother (1998) 1.48
Ectopic expression of the ErbB-3 binding protein ebp1 inhibits growth and induces differentiation of human breast cancer cell lines. J Cell Physiol (2000) 1.45
Trends among pathogens reported as causing bacteraemia in England, 2004-2008. Clin Microbiol Infect (2011) 1.44
Acute bacterial gastroenteritis: a study of adult patients with positive stool cultures treated in the emergency department. Emerg Med J (2003) 1.44
Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J Antimicrob Chemother (2010) 1.43
Mechanisms of beta-lactam resistance in British isolates of Pseudomonas aeruginosa. J Med Microbiol (1984) 1.41
Laboratory evaluation of an outbreak of nocardiosis in immunocompromised hosts. Am J Med (1981) 1.40
Multiresistant acinetobacter in the UK: how big a threat? J Hosp Infect (2004) 1.39
Evidence of clonal dissemination of multidrug-resistant Streptococcus pneumoniae in Hong Kong. J Clin Microbiol (1999) 1.39
Varicella exposure in a neonatal intensive care unit: emergency management and control measures. J Hosp Infect (1996) 1.38
Do beta-lactamases 'trap' cephalosporins? J Antimicrob Chemother (1985) 1.38
Transferable cephalosporin resistance not inhibited by clavulanate in Escherichia coli. Lancet (1990) 1.37
Healthcare-associated infections: think globally, act locally. Clin Microbiol Infect (2008) 1.35
Kinetics and significance of the activity of the Sabath and Abrahams' beta-lactamase of Pseudomonas aeruginosa against cefotaxime and cefsulodin. J Antimicrob Chemother (1983) 1.34